The qualifying criteria follow FDA-approved indications and established clinical guidelines
This flat-rate model removes the financial anxiety many patients feel when dose adjustments become necessary for optimal results
IGF-1 LR3 (1 mg) is a synthetic recombinant analog of insulin-like growth factor-1 (IGF-1), categorized under growth factor and muscle biology research peptides, and supplied exclusively for laboratory research use
The standard BPC-157 dosage is 250-500 mcg injected subcutaneously once or twice daily for 4-8 weeks, adjusted for injury type, body weight, and reconstitution concentration
This combination sometimes referred to in research literature under the investigational name CagriSema has become one of the most closely watched dual-peptide protocols in metabolic science: Pre-clinical studies have reported notably greater reductions in body weight markers when both compounds are used together compared to either alone, suggesting additive or synergistic effects through their distinct receptor pathways
Understanding these factors helps explain why some peptides work best via injection, while others require molecular modifications or specialized carriers for oral use
